Abstract:
En
|
Text:
En
|
PDF:
En
SUMMARY OBJECTIVE: The aim of this study was to evaluate the correlation between P-wave indexes, echocardiographic parameters, and CHA2DS2-VASc score in patients without atrial fibrillation and valvular disease. METHODS: This retrospective cross-sectional study included patients of a tertiary hospital with no history of atrial fibrillation, atrial flutter, or valve disease and collected data from June 2021 to May 2022. The exclusion criteria were as follows: unavailable medical records, pacemaker carriers, absence of echocardiogram report, or uninterpretable ECG. Clinical, electrocardiographic [i.e., P-wave duration, amplitude, dispersion, variability, maximum, minimum, and P-wave voltage in lead I, Morris index, PR interval, P/PR ratio, and P-wave peak time], and echocardiographic data [i.e., left atrium and left ventricle size, left ventricle ejection fraction, left ventricle mass, and left ventricle indexed mass] from 272 patients were analyzed. RESULTS: PR interval (RHO=0.13, p=0.032), left atrium (RHO=0.301, p<0.001) and left ventricle diameter (RHO=0.197, p=0.001), left ventricle mass (RHO=0.261, p<0.001), and left ventricle indexed mass (RHO=0.340, p<0.001) were positively associated with CHA2DS2-VASc score, whereas P-wave amplitude (RHO=-0.141, p=0.02), P-wave voltage in lead I (RHO=-0.191, p=0.002), and left ventricle ejection fraction (RHO=-0.344, p<0.001) were negatively associated with the same score. The presence of the Morris index was associated with high CHA2DS2-VASc (p=0.022). CONCLUSION: Prolonged PR interval, Morris index, increased left atrium diameter, left ventricle diameter, left ventricle mass, and left ventricle indexed mass values as well as lower P-wave amplitude, P-wave voltage in lead I, and left ventricle ejection fraction values were correlated with higher CHA2DS2-VASc scores. OBJECTIVE Pwave P wave indexes parameters CHA2DS2VASc CHADSVASc CHA2DS2 VASc CHA DS METHODS crosssectional cross sectional flutter 202 2022 follows records carriers report ECG Clinical i.e., ie i e [i.e. duration dispersion variability maximum minimum PPR ratio time, time , time] size 27 analyzed RESULTS RHO=0.13, RHO013 RHO 0 13 (RHO=0.13 p=0.032, p0032 p p=0.032 032 p=0.032) RHO=0.301, RHO0301 301 (RHO=0.301 p<0.001 p0001 001 RHO=0.197, RHO0197 197 (RHO=0.197 p=0.001, p=0.001 p=0.001) RHO=0.261, RHO0261 261 (RHO=0.261 p<0.001, RHO=0.340, RHO0340 340 (RHO=0.340 RHO=0.141, RHO0141 RHO= 0.141, 141 (RHO=-0.141 p=0.02, p002 p=0.02 02 p=0.02) RHO=0.191, RHO0191 0.191, 191 (RHO=-0.191 p=0.002, p0002 p=0.002 002 p=0.002) RHO=0.344, RHO0344 0.344, 344 (RHO=-0.344 p=0.022. p0022 p=0.022 . 022 (p=0.022) CONCLUSION scores CHADS CHA2DS 20 i.e. [i.e 2 RHO=0.13 RHO01 1 (RHO=0.1 p003 p=0.03 03 RHO=0.301 RHO030 30 (RHO=0.30 p<0.00 p000 00 RHO=0.197 RHO019 19 (RHO=0.19 p=0.00 RHO=0.261 RHO026 26 (RHO=0.26 RHO=0.340 RHO034 34 (RHO=0.34 RHO=0.141 RHO014 0141 0.141 14 (RHO=-0.14 p00 p=0.0 RHO=0.191 0191 0.191 (RHO=-0.19 RHO=0.344 0344 0.344 (RHO=-0.34 (p=0.022 i.e RHO=0.1 RHO0 (RHO=0. RHO=0.30 RHO03 3 (RHO=0.3 p<0.0 RHO=0.19 RHO=0.26 RHO02 (RHO=0.2 RHO=0.34 RHO=0.14 014 0.14 (RHO=-0.1 p0 p=0. 019 0.19 034 0.34 (RHO=-0.3 (p=0.02 RHO=0. (RHO=0 RHO=0.3 p<0. RHO=0.2 01 0.1 (RHO=-0. p=0 0.3 (p=0.0 RHO=0 (RHO= p<0 0. (RHO=-0 p= (p=0. (RHO p< (RHO=- (p=0 (p= (p